MUC5AC and Sepsis: Ramezanalizadeh et al. (22) conducted an initial study to evaluate two recombinant constructs, CsuA/B and FimA, as targets to develop protective antibodies against a lethal sepsis dose of 106 CFU A. baumannii ATCC 19606 mixed with 10% porcine mucin.